Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

It could occasionally present as asymptomatic microscopic hematuria or lower urinary tract symptoms (such as frequency, urgency and dysuria). In less than 10% of cases, the disease is diagnosed ...